Thermo Fisher Scientific research provides drug discovery insight

Thermo Fisher Scientific has announced that its collaborative research into drug discovery technology has successfully validated an emerging technique.

In association with Dr David Myszka, director of the Center for Biomolecular Interaction Analysis at the University of Utah, the company has been able to demonstrate the effectiveness of using surface plasmon resonance (SPR) to screen small molecules.

The research utilised the science company's Maybridge Ro3 Diversity Fragment Library to screen SPR molecules against stabilised G-Protein Coupled Receptors, thereby helping to identify new classes of compounds from the Ro3 library.

Dr Myszka noted that the integrity of the Maybridge library was instrumental to the project's success.

Simon Pearce, product manager for Maybridge products at Thermo Fisher Scientific, added: "The guaranteed aqueous solubility of Maybridge Ro3 Fragments is not only key from a practical perspective, but it also provides an insight into likely ADME problems as the hits are evolved into drug-like molecules."

Earlier this month, Thermo Fisher Scientific agreed a deal to purchase Dionex, a move that will allow it to expand its presence in the chromatography sector.